Dr. Jason Michael Melear, MD

Dr. Melear practices at Austin Midtown Ambulatory Surgery Center LLC in Austin, Texas.

Dr. Melear's NPI, 1902849805, was assigned on June 14, 2006. Dr. Melear graduated from Texas Tech University Health Sciences Center School of Medicine in 1996. Dr. Melear holds Texas license K3922.

Dr. Melear's primary practice is Austin Midtown Ambulatory Surgery Center LLC, at 901 W 38th St, Austin, TX 78705 in Travis County. The practice phone is (512) 992-0027.

Dr. Melear's primary practice is Austin Midtown Ambulatory Surgery Center LLC in Austin, Texas. Dr. Melear is also affiliated with St. David's Medical Center. The medical group on file is Texas Oncology. Dmand AI also links Dr. Melear to 2 more hospitals, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Melear practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Melear's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Melear is board certified in internal medicine by the American Board of Internal Medicine. Dr. Melear is licensed in Texas.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Melear treats.

CMS data shows 36,059 Medicare services from Dr. Melear across 53 procedure codes in 2024, for 533 Medicare patients. Medicare paid $586,036 for them.

CMS counts 533 Medicare patients who saw Dr. Melear in 2024. The largest group is 75 to 84, with 247 patients. 73% of them have high cholesterol, and 69% have high blood pressure. 6% are also on Medicaid. Their average risk score is 1.86, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Melear's median patient age at 72, with 56% women.

In 2024, Dr. Melear wrote 1,233 Medicare Part D claims for 179 patients. 54% of them were for generic drugs. CMS names the drug for 1,006 of them, across 30 drugs with 11 or more claims each, at $6,489,015 in total drug cost. In 2023, CMS named 900 claims across 29 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Melear for performance year 2024, reported through an alternative payment model (APM). Dr. Melear accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Melear as offering telehealth.

Dmand AI links 8 papers to Dr. Melear, published from 2019 to 2025. 2022 was the busiest year, with 2. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal and Bortezomib. Dr. Melear has published most often in Leuk Lymphoma. Dr. Melear's most frequent co-authors are Habte Aragaw Yimer, MD, John McEvoy Burke, MD and Pavani Chalasani, MD.

Dmand AI links Dr. Melear to 6 clinical trials, 2 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Lymphoma, Mantle-Cell, Lymphoma, Follicular and Leukemia, Myeloid, Acute. Bristol-Myers Squibb sponsors the most, 2. Open Payments lists research payments to Dr. Melear that name 2 trials.

CMS Open Payments shows 442 general payments to Dr. Melear from 53 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 75% of the total. Janssen Pharmaceuticals, Inc paid the most, $195,329. It also lists 19 research payments totaling $246,951 from 2016 to 2020, naming 2 clinical trials.

Dmand AI lists 2 awards for Dr. Melear, most recently Super Doc in 2012.

Dr. Melear graduated from Texas Tech University Health Sciences Center School of Medicine in 1996. Dr. Melear is a member of ACP.

Dr. Melear is in network with 23 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.